Scarica l'app Stockscreener
0.236
2.72%
-0.0066
Dopo l'orario di chiusura:
.23
-0.006
-2.54%
Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics to reduce board size as director term nears expiration By Investing.com - Investing.com Australia
Calidi Biotherapeutics (CLDI) Hinges on High-Stakes Q4 2026 IND Filing as Market Waits for Catalyst - Bitget
Calidi Biotherapeutics to reduce board size as director term nears expiration - Investing.com India
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks
Allan Camaisa to Leave Calidi Board; Scott Leftwich Joins Audit Committee - TradingView
Director transition leads Calidi Biotherapeutics (CLDI) to cut board size to five - Stock Titan
Calidi tees up new cancer-virus data before planned 2026 IND filing - Stock Titan
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Sahm
Calidi brings tumor-targeted immune therapy data to cancer meeting - Stock Titan
CLDI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor in Calidi Biotherapeutics (CLDI) discloses 0.3% stake - Stock Titan
VIX Spike: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Inflation Data: Is Calidi Biotherapeutics Inc forming a breakout pattern2026 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Calidi Biotherapeutics Reports 2025 Financial Results, Advances CLD-401 Clinical Development and Expands RedTail Platform Partnerships - Minichart
Calidi Biotherapeutics, Inc. 2025 Annual 10-K Report Highlights Equity, Warrants, and Financial Arrangements - minichart.com.sg
Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline - TipRanks
Calidi 2025 10-K: $20.24M operating loss, $20.06M net loss, $5.6M cash - TradingView
Calidi Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Calidi Biotherapeutics (CLDI) 10-K shows going-concern risk and early oncology pipeline - stocktitan.net
Calidi Biotherapeutics (NYSE: CLDI) reports 2025 loss and $5.6M cash - stocktitan.net
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - Bitget
Calidi Biotherapeutics released its financial results for the fourth quarter and full year of 2025, along with an update on its recent operational progress. - bitget.com
CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch - Intellectia AI
Market Pulse: Will Calidi Biotherapeutics Inc benefit from sector rotation2026 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Gap Down: Should I hold or sell Calidi Biotherapeutics Inc nowMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials - The Manila Times
Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval - TradingView
Calidi Biotherapeutics Announces Partnership with Avance - GlobeNewswire
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
Calidi Biotherapeutics prices $5.2M underwritten public offering - MSN
Big Picture: Can Calidi Biotherapeutics Inc keep up with sector leaders2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Portfolio Recap: How much upside does Calidi Biotherapeutics Inc have2026 Market Mood & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing - Sahm
Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit - Intellectia AI
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - Bitget
How a tumor-targeting virus therapy earned FDA support on its production - Stock Titan
Calidi Biotherapeutics Announces Proposed Public Offering of Common Stock and Warrants to Fund Growth Initiatives 12 - Minichart
Calidi Biotherapeutics Completes Dilutive Public Equity Offering - TipRanks
Calidi Biotherapeutics announces underwritten public offering - Investing.com Nigeria
Calidi Biotherapeutics Raises $6.03 Million in Unit Offering; Adds Warrant Agent and Amends Legacy Warrants - TradingView
Calidi Biotherapeutics (NYSE: CLDI) closes $6M unit and warrant deal - Stock Titan
Portfolio Update: Is Calidi Biotherapeutics Inc a stock for growth or value investors2026 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
CLDI PE Ratio & Valuation, Is CLDI Overvalued - Intellectia AI
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - Bitget
Calidi Biotherapeutics closes $6M public offering By Investing.com - Investing.com Canada
Calidi Biotherapeutics Announces Closing of $6.0 Million - GlobeNewswire
Calidi Biotherapeutics closes $6M public offering - Investing.com
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option - The Manila Times
Biotech Calidi raises $6M now, lines up $12M more with new warrants - Stock Titan
Investor Ognian Gavrilov reports 9.8% Calidi Biotherapeutics (CLDI) stake in Schedule 13D - Stock Titan
Calidi Biotherapeutics Prices $5.2 Mln Public Offering Of Shares And Warrants - Nasdaq
Published on: 2026-03-07 11:34:48 - baoquankhu1.vn
Growth Value: Is Calidi Biotherapeutics Inc forming a bullish divergenceTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
0.49%
1.47%
Capitalizzazione:
|
Volume (24 ore):